He points to preliminary signs that the drugs may curb cravings for addictive substances, but says stronger data should come before wider access.
Recap by typeshit. Post by John Arnold on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A shared excerpt points to TRIUMPH-2 results on how well retatrutide works and how safe it is. The snippet gives no numbers, so the full piece has the data.
Generic makers gain ground as another layer of semaglutide protection falls, per Life Sciences IP Review. Full story is behind a paywall.
Loading…